BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 8841500)

  • 1. Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
    Hájek R; Vorlicek J; Slavik M
    Neoplasma; 1996; 43(3):141-54. PubMed ID: 8841500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Paclitaxel (Taxol)].
    Hájek R
    Cas Lek Cesk; 1996 Jun; 135(12):393-6. PubMed ID: 8706079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
    Yamazaki S; Sekine I; Saijo N
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):605-15. PubMed ID: 9530372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacoeconomics of cancer therapies.
    Bishop JF; Macarounas-Kirchman K
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-106-S19-111. PubMed ID: 9427279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME
    Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.
    Gregory RE; DeLisa AF
    Clin Pharm; 1993 Jun; 12(6):401-15. PubMed ID: 7691462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel and carboplatin for advanced breast cancer.
    Perez EA; Hartmann LC
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):41-5. PubMed ID: 8893899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel pharmacology and other tumor types.
    Rowinsky EK
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-1-S19-12. PubMed ID: 9427257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel: current developmental approaches of the National Cancer Institute.
    Arbuck SG
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):55-63. PubMed ID: 8643972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Mayerhofer K; Kucera E; Zeisler H; Speiser P; Reinthaller A; Sevelda P
    Gynecol Oncol; 1997 Jan; 64(1):109-13. PubMed ID: 8995557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
    Wu H; Guan Z; Lin T
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
    Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
    Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
    Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Paclitaxel].
    Díaz M; Campanero MA
    Rev Med Univ Navarra; 1996; 40(3):43-51. PubMed ID: 9499826
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evidenced-based medicine and future direction of Taxol].
    Hatae M; Nakamura T; Ohnishi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1279-87. PubMed ID: 10945027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-small cell lung cancer: a phase II study by the Fox Chase Cancer Center Network.
    Langer CJ; Millenson M; O'Dwyer P; Kosierowski R; Alexander R; Litwin S; McAleer CA; Bonjo CA; Ozols R
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):35-41. PubMed ID: 9007119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
    Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.